# US 2026/0248961 A1 · Utilization of a hibernation-like state in neurological diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248961 A1
- Document ID: US20260248961A1
- Status: Published application
- Kind: A1
- Application number: 18/879,494
- Filed: 2023-05-31
- Published: 2026-08-27
- Earliest claimed: 2022-06-29
- Assignees: Okinawa Institute of Science and Technology School Corporation
- Applicants: Okinawa Institute of Science and Technology School Corporation
- Inventors: Kazumasa NAKAZAWA; Thato Mary MOKHOTHU; Yu-ju LIN; Miyu NAMBU
- Web page: https://patentgrep.com/patent/US20260248961A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 25/08: Antiepileptics; Anticonvulsants
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 2207/20: Animals treated with compounds which are neither proteins nor nucleic acids
- A01K 2207/35: Animals modified by environmental factors, e.g. temperature, O2
- A01K 2227/105: Murine
- A01K 2267/035: Animal model for multifactorial diseases
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The purpose of this invention is to provide a new treatment method for epilepsy that solves the problems of current epilepsy treatment and has long-term effects. The present invention is a method of treating a disease, comprising inducing hypothermia or hypometabolism in a subject. Thermoregulatory or metabolic regulatory neurons are stimulated in the step of inducing hypothermia or hypometabolism in the subject. Q neurons are stimulated in the step of inducing hypothermia or hypometabolism in the subject.

## Claims

### Claim 1

A method of treating a disease, the method comprising inducing hypothermia or hypometabolism in a subject in need thereof.

### Claim 2 (depends on 1)

The method of treating a disease according to claim 1, the method comprising stimulating a thermoregulatory or metabolic regulatory neuron to induce hypothermia or hypometabolism in the subject.

### Claim 3 (depends on 2)

The method of treating a disease according to claim 2, wherein the thermoregulatory or metabolic regulatory neuron is a Q neuron.

### Claim 4 (depends on 1)

The method of treating a disease according to claim 1, wherein the disease is a neurological disease.

### Claim 5 (depends on 4)

The method of treating a disease according to claim 4, wherein the neurological disease is epilepsy.

### Claim 6 (depends on 5)

The method of treating a disease according to claim 5, wherein the epilepsy is temporal lobe epilepsy (TLE).

### Claim 7 (depends on 5)

The method of treating a disease according to claim 5, wherein the inducing hypothermia or hypometabolism in the subject is performed during a latent phase of the disease.

### Claim 8 (depends on 5)

The method of treating a disease according to claim 5, wherein the treating comprises delaying a seizure.

### Claim 9 (depends on 5)

The method of treating a disease according to claim 5, wherein the treating comprises alleviating a seizure.

### Claim 10 (depends on 1)

The method of treating a disease according to claim 1, wherein the subject is a mammal.

### Claim 11

A kit for treating a neurological disease, comprising a recombinant vector comprising a gene encoding a protein that functions to specifically stimulate thermoregulatory or metabolic regulatory neurons and a compound for activating thermoregulatory or metabolic regulatory neurons.

### Claim 12 (depends on 11)

The kit for treating a neurological disease according to claim 11, wherein the thermoregulatory or metabolic regulatory neurons are Q neurons.

### Claim 13 (depends on 12)

The kit for treating a neurological disease according to claim 12, wherein the gene is a hM3Dq gene operably linked to a QRFP (pyroglutamylated RFamide peptide) promoter, and the compound is clozapine-N-oxide.

### Claim at position 14

14-15. (canceled)

### Claim 16

A method for treating a neurological disease, comprising administering to a subject in need thereof a recombinant vector comprising a gene encoding a photosensitive protein for specifically stimulating thermoregulatory or metabolic regulatory neurons in the subject in response to light, and irradiating said neurons with light.

### Claim 17 (depends on 16)

The method of claim 16, wherein the photosensitive protein is channelrhodopsin, and wherein the gene encoding channelrhodopsin is operably linked to a QRFP promoter.

### Claim 18

A method of treating a neurological disease, comprising administering to a subject in need thereof a compound for stimulating thermoregulatory or metabolic regulatory neurons in a subject and a recombinant vector comprising a gene encoding a receptor for specifically stimulating the thermoregulatory or metabolic regulatory neurons in response to the compound.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the recombinant vector comprises a hM3Dq gene and operably linked to a QRFP promoter, and the compound is clozapine-N-oxide.
